About Edesa Biotech
Edesa Biotech (NASDAQ:EDSA) is a biopharmaceutical company focused on inflammatory and immune-related diseases. Their operations span the development and commercialization of innovative therapeutics aimed at treating conditions that lack effective treatments. With a keen eye on advancing its research and development, Edesa Biotech's projects include working on novel therapies for dermatological diseases, gastrointestinal disorders, and other acute inflammatory conditions. The company is steadfast in its objective to bring breakthrough solutions to patients, aiming to address the unmet medical needs through its pipeline of potential treatments. By leveraging cutting-edge science and a passion for healing, Edesa Biotech is dedicated to improving patient outcomes and transforming lives through innovation.
Snapshot
Operations
Produtos e/ou serviços de Edesa Biotech
- EB05, a monoclonal antibody designed for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients.
- EB01, a novel sPLA2 inhibitor for chronic allergic contact dermatitis.
- EB02, an innovative treatment targeting chronic pruritus.
- A partnership aimed at developing a range of dermatological treatments targeting unmet medical needs.
- Patented technology platform for the identification and rapid development of monoclonal antibodies.
- Strategic collaborations with global pharmaceutical companies to expand the distribution and reach of its dermatology and critical care portfolio.
equipe executiva do Edesa Biotech
- Dr. Pardeep Nijhawan FRCPC, M.D.CEO, Company Secretary & Director
- Dr. Michael J. Brooks M.B.A., Ph.D.President
- Mr. Peter John Weiler M.B.A, M.Sc.Chief Financial Officer